Some inhibitors targeting lipid metabolism in RCC such as SR9243 and liver X receptor-623 have been confirmed to be effective in vivo or in vitro trials, but no drugs targeting LDL or LDLR have been reported [7]. The gene discussed is LDLR; the disease is renal cell carcinoma.